Finch Therapeutics Group Inc

NASDAQ:FNCHUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Finch Therapeutics Group, Inc. is a clinical-stage microbiome therapeutics company. It is engaged in leveraging its Human-First Discovery platform to develop a class of orally administered biological drugs. Its Human-First Discovery platform uses reverse translation to identify diseases of dysbiosis and to design microbiome therapeutics that address them. Its lead product candidate, CP101, is an orally administered complete microbiome therapeutic in development for the prevention of recurrent Clostridioides difficile infection (CDI). CP101, consists of a microbial community harvested from rigorously screened healthy donors that is lyophilized and formulated in orally administered capsules designed to release at the appropriate location in the gastrointestinal tract. CP101 is designed to deliver a complete microbiome, addressing the community-level dysbiosis that characterizes CDI. Its product pipeline includes FIN-211, TAK-524, and FIN-525, as well as consortia product candidates.

Contact Information

Headquarters

200 Inner Belt RoadSOMERVILLE, MA, United States 02143

Phone

617-229-6499

Fax

302-636-5454

Executives

Non-Executive Independent Chairman of the Board

Susan Graf

President, Chief Executive Officer, Director

Mark Smith

Principal Financial Officer, Chief Operating Officer

Marc Blaustein

Senior Vice President, Late-Stage Development and GI Therapeutic Area Lead

Howard Franklin

Chief Technology Officer

Bryan Gillis